Suchergebnisse - "Touzeau, Cyrille"

PubPharm (12)

1

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma : an IFM randomized phase 3 study

enthalten in: Blood | 2022

von Roussel, M. | Lauwers-Cances, V. | Macro, M. | +56

ErratumIn: Blood. 2023 Mar 9;141(10):1234. - PMID 36893003

2

Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma : Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019

enthalten in: British journal of haematology | 2022

von Swan, D. | Hayden, P. | Eikema, D. | +22

3

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA) : an open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2021

von Moreau, P. | Hulin, C. | Perrot, A. | +49

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34545220

4

Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES) : an open-label Phase II study

enthalten in: British journal of haematology | 2021

von Chari, A. | Rodriguez-Otero, P. | McCarthy, H. | +18

5

Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma : a single-center experience

enthalten in: Bone marrow transplantation | 2021

von Laurent, V. | Fronteau, C. | Antier, C. | +22

6

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA) : a randomised, open-label, phase 3 study

enthalten in: Lancet (London, England) | 2019

von Moreau, P. | Attal, M. | Hulin, C. | +55

CommentIn: Lancet. 2019 Jul 6;394(10192):3-4. - PMID 31171418

7

Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM

enthalten in: Blood | 2017

von Moreau, P. | Chanan-Khan, A. | Roberts, A. | +16

CommentIn: Blood. 2017 Nov 30;130(22):2359-2360. - PMID 29191974

8

Triplet combinations in relapsed/refractory myeloma : update on recent phase 3 trials

enthalten in: Expert review of hematology | 2017

von Boudreault, J. | Touzeau, C. | Moreau, P.

9

Quisinostat, bortezomib, and dexamethasone combination therapy for relapsed multiple myeloma

enthalten in: Leukemia & lymphoma | 2016

von Moreau, P. | Facon, T. | Touzeau, C. | +10

10

New data on subcutaneous bortezomib

enthalten in: Acta haematologica | 2015

von Moreau, P. | Touzeau, C.

CommentOn: Acta Haematol. 2015;133(1):29-30. - PMID 24993672